Company: SRPT
Filing Date: 2025-08-06
Form Type: S-8
Source: 0001193125-25-174466
Chunk: 0

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-08-06
Form: S-8
Chunk 0
---
As filed with the Securities and Exchange Commission on August 6, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sarepta Therapeutics, Inc. (Exact name of registrant as specified in its charter)

| Delaware                        |     | 93-0797222         |
| (State or other jurisdiction of 
 incorporation or organization)  |     | -I.R.S. Employer   
 Identification No. |

215 First Street, Suite 415 Cambridge, Massachusetts 02142 (Address of Principal Executive Offices) (Zip Code) Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan, as amended Sarepta Therapeutics, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (as amended and restated on June 27, 2016), as amended (Full title of the plan) Douglas S. Ingram Chief Executive Officer Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, Massachusetts 02142 (Name and address of agent for service) (617) 274-4000 (Telephone number, including area code, of agent for service) Copies to: Paul M. Kinsella William J. Michener Ropes & Gray LLP Prudential Tower 800 Boylston Street Boston, Massachusetts 02199 (617) 951-7000 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-acceleratedfiler, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2of the Exchange Act.

| Large accelerated filer |     | ☒ |     | Accelerated filer         |     | ☐ |
| Non-accelerated filer   |     | ☐ |     | Smaller reporting company |     | ☐ |
|                         |     |   |     | Emerging growth company   |     | ☐ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐